普拉曲沙：治疗 T 细胞非霍奇金淋巴瘤。

Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.

机构信息

Department of Internal Medicine (Hematology), Yale University School of Medicine, 333 Cedar Street, PO Box 208032, New Haven, CT 06520, USA.

出版信息

Future Oncol. 2013 Jan;9(1):21-9. doi: 10.2217/fon.12.168.

DOI:10.2217/fon.12.168

PMID:23252560

Abstract

Pralatrexate is a folate analogue metabolic inhibitor manufactured by Allos Therapeutics, Inc., a wholly-owned subsidiary of Spectrum Pharmaceuticals, Inc. In both preclinical and clinical studies, pralatrexate demonstrated activity in lymphoma. Pralatrexate was US FDA approved for the treatment of relapsed/refractory peripheral T-cell lymphoma in 2009. Approval was based on data from the PROPEL trial that demonstrated an overall response rate of 29% in a heavily pretreated patient population. The dose and schedule of pralatrexate is 30-mg/m(2) weekly for 6 weeks, given in 7-week cycles. Folate and vitamin B12 supplementation are required to minimize toxicity. The most common toxicities are mucositis, thrombocytopenia, nausea and fatigue.

摘要

普拉曲沙是一种叶酸类似物代谢抑制剂，由 Allos Therapeutics, Inc. 生产，该公司是 Spectrum Pharmaceuticals, Inc. 的全资子公司。在临床前和临床研究中，普拉曲沙在淋巴瘤中表现出活性。普拉曲沙于 2009 年获得美国食品和药物管理局批准用于治疗复发/难治性外周 T 细胞淋巴瘤。批准基于 PROPEL 试验的数据，该试验表明在预处理过的患者人群中总体缓解率为 29%。普拉曲沙的剂量和方案为每周 30mg/m(2)，持续 6 周，每 7 周为一个周期。需要补充叶酸和维生素 B12 以最大程度地减少毒性。最常见的毒性是黏膜炎、血小板减少症、恶心和疲劳。